Triiodothyronine use in hypothyroidism and its effects on cancer and mortality.

CONCLUSIONS: In this large Swedish long-term register-based study, the use of T3 did not lead to increased breast cancer incidence, any cancer incidence, all-cause mortality, any cancer mortality, or breast cancer mortality compared to T4 use. Somewhat surprisingly, there was evidence of lower mortality in T3 users in models adjusting for dose, potentially an artifact of underlying associations between dose and health status/diagnosis. PMID: 33040688 [PubMed - as supplied by publisher]
Source: Thyroid : official journal of the American Thyroid Association - Category: Endocrinology Tags: Thyroid Source Type: research